PO-S03: GLP-1/GIP/Glucagon Triple Agonist

PO-S03 (LY3437943) is a synthetic peptide that acts as a triple agonist at the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). Developed by Eli Lilly, it represents the latest evolution in incretin-based research compounds, moving beyond single (GLP-1R) and dual (GLP-1R/GIPR) agonism to simultaneous engagement of three metabolic receptors.

PO-S03 is a 39-amino acid peptide based on a GIP backbone sequence with modifications that confer activity at GLP-1R and GCGR. It includes a fatty acid moiety conjugated to a lysine residue that extends its half-life by promoting albumin binding, enabling once-weekly administration in research workflows.

The addition of glucagon receptor agonism distinguishes PO-S03 from earlier dual agonists like PO-S02 (GLP-1R/GIPR). Glucagon receptor activation stimulates hepatic energy expenditure, thermogenesis, and lipolysis — effects that complement the appetite-suppressing and insulin-sensitizing actions of GLP-1R and GIPR activation. This triple mechanism creates a distinct pharmacological profile that is the subject of active preclinical and clinical investigation.

Understanding the contribution of each receptor is essential for interpreting PO-S03 research.

**GLP-1 receptor (GLP-1R):** Activation promotes glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon secretion (in the fed state), slows gastric emptying, and activates central satiety circuits in the hypothalamus and brainstem. GLP-1R agonism is the established backbone of incretin pharmacology, with well-characterized effects on glycemic control and appetite.

**GIP receptor (GIPR):** Activation amplifies glucose-dependent insulin secretion in concert with GLP-1R. GIPR agonism also appears to modulate adipose tissue function — preclinical data suggest it promotes lipid buffering capacity in adipocytes and may enhance the tolerability of GLP-1R agonism by attenuating nausea. The metabolic role of GIP is more context-dependent than GLP-1, with both agonism and antagonism showing beneficial metabolic effects in different experimental settings.

**Glucagon receptor (GCGR):** This is the novel component. Glucagon receptor activation stimulates hepatic glycogenolysis and gluconeogenesis (raising blood glucose acutely), but also increases hepatic fatty acid oxidation, energy expenditure, and thermogenesis. In the context of simultaneous GLP-1R activation (which counterbalances the hyperglycemic effect), GCGR agonism adds energy expenditure and hepatic lipid clearance without net hyperglycemia.

**Synergy:** The three-receptor approach creates a pharmacological profile where GLP-1R/GIPR activation handles glycemic control and appetite, while GCGR activation adds energy expenditure and hepatic lipid metabolism. The glycemic balance is maintained because GLP-1R-mediated insulin secretion and glucagon suppression counteract GCGR-mediated glucose production.

PO-S03 has been characterized in both preclinical models and early-phase human studies.

PO-S03 represents the third generation of incretin-based research compounds:

**Generation 1 — GLP-1R mono-agonists:** Exenatide (exendin-4 based, short-acting), liraglutide (acylated GLP-1 analog, daily), po-s01 (further modified, weekly). Established the GLP-1R agonist class. Primary effects: glycemic control and appetite suppression.

**Generation 2 — Dual GLP-1R/GIPR agonists:** PO-S02 is the prototype. Adding GIPR agonism amplifies insulin secretion and may improve tolerability. Produces greater metabolic effects than GLP-1R mono-agonism in comparative studies.

**Generation 3 — Triple GLP-1R/GIPR/GCGR agonists:** PO-S03 adds glucagon receptor activation, introducing energy expenditure and hepatic lipid clearance as additional mechanisms. Early data suggest incremental metabolic effects beyond dual agonism.

This progression illustrates a broader trend in incretin research: from single-target to multi-target approaches that engage complementary metabolic pathways simultaneously. Each step adds mechanistic complexity but also expands the pharmacological toolbox available to metabolic researchers.

PO-S03 is an advanced research compound with specific handling requirements:

**Receptor deconvolution:** To isolate the contribution of each receptor, include control groups with selective single agonists (GLP-1R agonist alone, GIPR agonist alone, GCGR agonist alone) and dual agonists (PO-S02-class). GCGR-knockout mice can confirm glucagon receptor-dependent effects.

**Gastrointestinal monitoring:** GLP-1R-mediated slowing of gastric emptying is a common observation. Include gastric emptying measurements (acetaminophen absorption test or phenol red gavage) to characterize GI effects.

**Storage:** Store lyophilized material at -20°C. Prepared solutions at 2-8°C for up to 14 days. The fatty acid modification provides some stability advantage over unmodified peptides.

*All materials are for research use only.*